AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32990206 — intervention group
Group type: COMPARATOR
Intervention: Combination sedation (propofol with midazolam, fentanyl, dexmedetomidine, and/or ketamine)
Number of subjects: 277
Study 35108470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 970
Study 35108470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 970
Study 35108470 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 970
Study 34156534 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 20
Study 34156534 — intervention group
Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 20
Study 34156534 — intervention group
Group type: COMPARATOR
Intervention: Resting
Number of subjects: 20
Study 35690060 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐cigarettes with 30 mg/g nicotine in e‐liquid
Number of subjects: 23
Study 35690060 — intervention group
Group type: COMPARATOR
Intervention: conventional cigarettes
Number of subjects: 23
Study 34039736 — intervention group
Group type: EXPERIMENTAL
Intervention: 22‐gage Tuohy needle
Number of subjects: 204
Study 34039736 — intervention group
Group type: COMPARATOR
Intervention: 22‐gage Quincke needle
Number of subjects: 204
Study 33070517 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (10 Hz repetitive transcranial magnetic stimulation delivered to the left dorsolateral prefrontal cortex at 80% of the resting motor threshold)
Number of subjects: 27
Study 33070517 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (10 Hz repetitive transcranial magnetic stimulation)
Number of subjects: 27
Study 33070517 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham stimulation)
Number of subjects: 27
Study 36063821 — intervention group
Group type: EXPERIMENTAL
Intervention: Asundexian 10 mg
Number of subjects: 1808
Study 36063821 — intervention group
Group type: EXPERIMENTAL
Intervention: Asundexian 20 mg
Number of subjects: 1808
Study 36063821 — intervention group
Group type: EXPERIMENTAL
Intervention: Asundexian 50 mg
Number of subjects: 1808
Study 36063821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1808
Study 33872982 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolgolimab 1 mg/kg every 2 weeks (arm 1)
Number of subjects: 126
Study 33872982 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolgolimab 3 mg/kg every 3 weeks (arm 2)
Number of subjects: 126
Study 32429063 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP‐1703
Number of subjects: 95
Study 34480657 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 0
Study 34480657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33403448 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (Group A), chewed for 30 min every 8 hours starting 6 hours post-operation
Number of subjects: 100
Study 33403448 — intervention group
Group type: COMPARATOR
Intervention: No chewing gum (Group B)
Number of subjects: 100
Study 33403448 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (Group A)
Number of subjects: 100
Study 35803640 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment questionnaires (MADRS-S, GAD-7, KEDS)
Number of subjects: 341
Study 35803640 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of own poor work ability
Number of subjects: 341
Study 34588237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (first dose)
Number of subjects: 700
Study 34588237 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA‐BN‐Filo (second dose)
Number of subjects: 700
Study 34588237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (booster dose)
Number of subjects: 700
Study 34588237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (first dose) to Ad26.ZEBOV (booster dose)
Number of subjects: 700
Study 36428044 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused approach (7-session program of anger management and prevention of violent behavior)
Number of subjects: 48
Study 34110392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 34110392 — intervention group
Group type: COMPARATOR
Intervention: Active comparators
Number of subjects: 181
Study 34110392 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 181
Study 34110392 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blinded trials
Number of subjects: 181
Study 34110392 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes as primary efficacy endpoint
Number of subjects: 181
Study 34110392 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 2 pivotal trials for supplemental approvals
Number of subjects: 181
Study 34110392 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 2 pivotal trials for original approvals
Number of subjects: 181
Study 34110392 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial duration of 12 months or more for original approvals
Number of subjects: 181
Study 34110392 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial duration of 12 months or more for supplemental approvals
Number of subjects: 181
Study 32513229 — intervention group
Group type: EXPERIMENTAL
Intervention: Active peeling of the internal limiting membrane (ILM)
Number of subjects: 106
Study 32513229 — intervention group
Group type: COMPARATOR
Intervention: No peeling of the internal limiting membrane (ILM)
Number of subjects: 106
Study 35048389 — intervention group
Group type: EXPERIMENTAL
Intervention: ELEVATE
Number of subjects: 929
Study 35048389 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples Connecting Mindfully (CCM)
Number of subjects: 929
Study 35048389 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 929
Study 32312139 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing removal at 24 hours
Number of subjects: 0
Study 32312139 — intervention group
Group type: COMPARATOR
Intervention: Dressing removal at 48 hours
Number of subjects: 0
Study 33602588 — intervention group
Group type: EXPERIMENTAL
Intervention: Long tourniquet (LT) time
Number of subjects: 100
Study 33602588 — intervention group
Group type: COMPARATOR
Intervention: Short tourniquet (ST) time
Number of subjects: 100
Study 36380971 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg tablets daily for four weeks
Number of subjects: 90
Study 36380971 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg tablets twice daily for four weeks
Number of subjects: 90
Study 32895855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36161108 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus caloric restriction
Number of subjects: 185
Study 36161108 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet alone
Number of subjects: 185
Study 36161108 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 185
Study 36032439 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vestibular stimulation
Number of subjects: 30
Study 36032439 — intervention group
Group type: COMPARATOR
Intervention: Traditional balance exercises
Number of subjects: 30
Study 35766956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg for bolus over 10 min before induction of anesthesia, 1.5 mg/kg/h for continuous infusion)
Number of subjects: 160
Study 35766956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/kg for bolus over 10 min before induction of anesthesia, 0.4 µg/kg/h for continuous infusion)
Number of subjects: 160
Study 35766956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus Dexmedetomidine (Lidocaine: 1.5 mg/kg for bolus over 10 min before induction of anesthesia, 1.5 mg/kg/h for continuous infusion; Dexmedetomidine: 0.5 µg/kg for bolus over 10 min before induction of anesthesia, 0.4 µg/kg/h for continuous infusion)
Number of subjects: 160
Study 35766956 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 160
Study 33773628 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 0
Study 33773628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33833179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration analgesia using the Buzzy device
Number of subjects: 100
Study 33833179 — intervention group
Group type: COMPARATOR
Intervention: Control group (propofol infusion without vibration analgesia)
Number of subjects: 100
Study 34972028 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-based video (IG-1, n = 222)
Number of subjects: 626
Study 34972028 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-based video plus psychoeducational video (IG-2, n = 216)
Number of subjects: 626
Study 34972028 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 188)
Number of subjects: 626
Study 33667587 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy (CRT)
Number of subjects: 111
Study 33667587 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant gemcitabine alone
Number of subjects: 111
Study 35944270 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification program with mobile app
Number of subjects: 112
Study 35944270 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 32997437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory positive expiratory pressure therapy (OPEPT)
Number of subjects: 0
Study 32997437 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chest physiotherapy (CCP)
Number of subjects: 0
Study 32997437 — intervention group
Group type: COMPARATOR
Intervention: OPEPT
Number of subjects: 0
Study 32997437 — intervention group
Group type: COMPARATOR
Intervention: CCP
Number of subjects: 0
Study 35190420 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Is insulin right for me?' (intervention)
Number of subjects: 392
Study 35190420 — intervention group
Group type: COMPARATOR
Intervention: Widely available online resources (control)
Number of subjects: 392
Study 32691639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichrostachys glomerata (DG; 300 mg/d)
Number of subjects: 68
Study 32691639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichrostachys glomerata with caffeine (DG + C)
Number of subjects: 68
Study 33035472 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate
Number of subjects: 1708
Study 33035472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1708
Study 616500056 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored group
Number of subjects: 127
Study 616500056 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study 35577699 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics features based on lung CT using supervised machine learning
Number of subjects: 252
Study 35577699 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM model for two-class differentiation
Number of subjects: 252
Study 33590342 — intervention group
Group type: EXPERIMENTAL
Intervention: Beach tennis session
Number of subjects: 24
Study 33590342 — intervention group
Group type: COMPARATOR
Intervention: Control session (seated rest)
Number of subjects: 24
Study 35704218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcium gluconate (IV) 10% (n = 30)
Number of subjects: 60
Study 35704218 — intervention group
Group type: COMPARATOR
Intervention: Oral elemental calcium (n = 30)
Number of subjects: 60
Study 35704218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcium gluconate (IV) 10%
Number of subjects: 60
Study 35704218 — intervention group
Group type: COMPARATOR
Intervention: Oral elemental calcium
Number of subjects: 60
Study 33427749 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific CD8+ T cell responses
Number of subjects: 30
Study 33427749 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific T cells
Number of subjects: 30
Study 33427749 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell differentiation
Number of subjects: 30
Study 33427749 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune response modeling
Number of subjects: 30
Study 33455112 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOT neoadjuvant chemotherapy with omega 3
Number of subjects: 42
Study 33455112 — intervention group
Group type: COMPARATOR
Intervention: FLOT chemotherapy alone
Number of subjects: 42
Study 36105936 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent combined with laparoscopic therapeutic based on ERAS
Number of subjects: 60
Study 36105936 — intervention group
Group type: COMPARATOR
Intervention: Stent combined with laparoscopic therapeutic
Number of subjects: 60
Study 33977587 — intervention group
Group type: EXPERIMENTAL
Intervention: Home physical exercise and sleep hygiene
Number of subjects: 125
Study 32453377 — intervention group
Group type: EXPERIMENTAL
Intervention: Viltolarsen 40 mg/kg per week
Number of subjects: 16
Study 32453377 — intervention group
Group type: EXPERIMENTAL
Intervention: Viltolarsen 80 mg/kg per week
Number of subjects: 16
Study 32453377 — intervention group
Group type: COMPARATOR
Intervention: Control (natural history controls)
Number of subjects: 16
Study 35108294 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use preventive intervention arm (short handbook, two meetings with interventionist, two SMS messages per week)
Number of subjects: 500
Study 35108294 — intervention group
Group type: COMPARATOR
Intervention: Attention-control condition (same dose as intervention but focused on nutrition, physical activity, and weight stigma)
Number of subjects: 500
Study 35108294 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use preventive intervention arm
Number of subjects: 500
Study 32991907 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning/image recognition model trained with 627 images
Number of subjects: 1169
Study 32991907 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning/image recognition model trained with 1169 images
Number of subjects: 1169
Study 32991907 — intervention group
Group type: COMPARATOR
Intervention: Inter-rater analysis among expert pediatric urologists
Number of subjects: 1169
Study 32991907 — intervention group
Group type: COMPARATOR
Intervention: Intra-rater analysis among expert pediatric urologists
Number of subjects: 1169
Study 35529427 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 38
Study 35529427 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) and Adipose-Derived Mesenchymal Stem Cells (AD-MSCs) injection
Number of subjects: 38
Study 35529427 — intervention group
Group type: COMPARATOR
Intervention: Control group (microfracture only)
Number of subjects: 38
Study 33326576 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Number of subjects: 2153
Study 36049266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor insoles (N=28)
Number of subjects: 73
Study 36049266 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporting insoles (N=23)
Number of subjects: 73
Study 36049266 — intervention group
Group type: COMPARATOR
Intervention: Placebo insoles (N=22)
Number of subjects: 73
Study 36049266 — intervention group
Group type: COMPARATOR
Intervention: Control group (Placebo insoles)
Number of subjects: 73
Study 34148181 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured chaplain intervention (12 sessions of 50 minutes each)
Number of subjects: 2
Study 34148181 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2
Study 35860417 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 84
Study 35860417 — intervention group
Group type: COMPARATOR
Intervention: Sham electro-acupuncture (SA)
Number of subjects: 84
Study 35860417 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (medication group)
Number of subjects: 84
Study 35385934 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS+HDM
Number of subjects: 6
Study 35385934 — intervention group
Group type: COMPARATOR
Intervention: PBS+HDM
Number of subjects: 6
Study 35385934 — intervention group
Group type: COMPARATOR
Intervention: PBS+PBS
Number of subjects: 6
Study 33096556 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA concentration
Number of subjects: 659
Study 33096556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin concentration
Number of subjects: 659
Study 33096556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactalbumin concentration
Number of subjects: 659
Study 33096556 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute abundance of HMOs (among secretors)
Number of subjects: 659
Study 33096556 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative abundance of fucosylated HMOs (among secretors)
Number of subjects: 659
Study 33096556 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative abundance of sialylated HMOs (among secretors)
Number of subjects: 659
Study 33096556 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopontin concentration (among secretors)
Number of subjects: 659
Study 36374502 — intervention group
Group type: EXPERIMENTAL
Intervention: CO‐IMPACT intervention
Number of subjects: 239
Study 36374502 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 239
Study 35132039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment targeting SBP of less than 120 mmHg
Number of subjects: 9361
Study 35132039 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment targeting SBP of less than 140 mmHg
Number of subjects: 9361
Study 35132039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 9361
Study 32341044 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity nerve decompression surgery (LEND)
Number of subjects: 344
Study 32341044 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-surgical care
Number of subjects: 344
Study 36256688 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-SH (superhero avatar)
Number of subjects: 30
Study 36256688 — intervention group
Group type: COMPARATOR
Intervention: VR-Play (neutral avatar)
Number of subjects: 30
Study 36256688 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (VR-SH and VR-Play)
Number of subjects: 30
Study 33873028 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (GMI)
Number of subjects: 118
Study 33873028 — intervention group
Group type: COMPARATOR
Intervention: Treatment-Control (TCC)
Number of subjects: 118
Study 34653660 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg in addition to standard therapeutic care)
Number of subjects: 158
Study 34653660 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapeutic care only)
Number of subjects: 158
Study 34407343 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atogepant
Number of subjects: 873
Study 34407343 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg atogepant
Number of subjects: 873
Study 34407343 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg atogepant
Number of subjects: 873
Study 34407343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 873
Study 33216398 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively framed films in VR
Number of subjects: 146
Study 33216398 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively framed films in 2D
Number of subjects: 146
Study 33216398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear appeal films in VR
Number of subjects: 146
Study 33216398 — intervention group
Group type: COMPARATOR
Intervention: Fear appeal films in 2D
Number of subjects: 146
Study 32246706 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 195
Study 33307409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuned Random Forest (RF) model with 300 iterations and 10 variables
Number of subjects: 42257
Study 33307409 — intervention group
Group type: COMPARATOR
Intervention: Multinomial Logistic Regression (MLR) model
Number of subjects: 42257
Study 33307409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuned Random Forest (RF) model
Number of subjects: 42257
Study 33037961 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy (GCBT) for 8 weeks
Number of subjects: 40
Study 33037961 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 36229981 — intervention group
Group type: EXPERIMENTAL
Intervention: Early time-restricted feeding (eTRF) for 12 months
Number of subjects: 25
Study 36229981 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum feeding
Number of subjects: 25
Study 33830064 — intervention group
Group type: EXPERIMENTAL
Intervention: Step Away mobile app
Number of subjects: 55
Study 35253564 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist‐ankle acupuncture
Number of subjects: 200
Study 35253564 — intervention group
Group type: COMPARATOR
Intervention: Control (false acupuncture)
Number of subjects: 200
Study 35094848 — intervention group
Group type: EXPERIMENTAL
Intervention: fevipiprant 150 mg
Number of subjects: 98
Study 35094848 — intervention group
Group type: EXPERIMENTAL
Intervention: fevipiprant 450 mg
Number of subjects: 98
Study 35094848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 32652205 — intervention group
Group type: EXPERIMENTAL
Intervention: Near visual acuity (VA)
Number of subjects: 6851
Study 32652205 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance visual acuity (VA)
Number of subjects: 6851
Study 32652205 — intervention group
Group type: COMPARATOR
Intervention: Overall eyesight subscale scores
Number of subjects: 6851
Study 32652205 — intervention group
Group type: COMPARATOR
Intervention: Difficulty in activities scores
Number of subjects: 6851
Study 32652205 — intervention group
Group type: COMPARATOR
Intervention: Social functioning scores
Number of subjects: 6851
Study 32297992 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg
Number of subjects: 0
Study 32297992 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 150 mg
Number of subjects: 0
Study 32297992 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg
Number of subjects: 0
Study 32297992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0